REMARKS

Claims 22 and 85 are pending.

Applicants hereby elect to pursue the invention of Group III, drawn to antibodies, as provided in claim 22, in the present application, without prejudice to the pursuance of the subject matter of non-elected claims in other patent applications. As a result of this election, Applicants cancel non-elected claims 3, 6, 8, 13, 14, 17-21, 48 and 62, without prejudice to the prosecution of the subejct matter of these claims in other patent applications.

In addition, claim 22 is amended to focus on OLD-35, without prejudice to the prosecution of subject matter relating to OLD-64, OLD-137, OLD-139, OLD-142 or OLD-175 proteins in other patent applications. Further, Applicants wish to disclose the following facts to the Examiner. After the filing of the priority applications relating to this application, Applicants discovered that the original sequence obtained for the OLD-35 gene contained an error or variation relative to the wild-type gene which resulted in a frame-shift mutation in the protein. Specifically, in the wild type nucleic acid sequence, there is a cytosine inserted at position 2089. The variation represented in the present application may have arisen from a cloning artifact when the library used to identify OLD-35 was produced. The nucleotide insertion in the naturally occurring sequence alters the reading frame, so that the amino acid sequence of the naturally occurring protein downstream of the insertion differs from that set forth in this patent application (SEQ ID NO:42) and is approximately 70 residues longer. That said, however, the amino acid sequence prior to the insertion at 2089 remains the same, so that the antibodies produced against the OLD-35 sequence disclosed herein would be reasonably expected to cross-react with native

OLD-35 protein.

In order to ensure that the claimed antibody is not reacting with protein downstream of the insertion, claim 22 is amended to require that the claimed antibody (or its antigen binding fragment) bind to a protein that is induced by interferon beta.

Finally, claim 85 is added, which provides for an antibody or antigen binding fragment thereof of claim 22 which is a monoclonal antibody. Prior attorneys for Applicants had cancelled original claim 23, which pertains to monoclonal antibodies, without explanation. Applicants believe that such antibodies properly should be considered within the scope of this application, and request that claim 85 be added.

Respectfully submitted,

BAKER BOTTS L.L.P.



Lisa B. Kole
Patent Office Reg. No. 35,225
Attorney for Applicant
(212) 408-2628